October 19, 2021
JCR Pharmaceuticals said on October 18 that it has received the European Medicines Agency’s (EMA) PRIME designation for JR-141 (pabinafusp alfa) for the treatment of mucopolysaccharidosis (MPS) II, also called Hunter syndrome. The Japanese company is currently preparing to initiate...read more